JPMorgan lowered the firm’s price target on Allogene Therapeutics to $9 from $11 and keeps an Overweight rating on the shares. The analyst updated models in the small cap biotechnology space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALLO:
- Short Report: Bearish position on Digital Ocean falls to five-month lows
- Allogene Therapeutics appoints Douglas as General Counsel
- Allogene Therapeutics reports Q2 EPS (53c), consensus (59c)
- Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
- ‘Too Cheap to Ignore’: J.P. Morgan Says These 2 Stocks Under $10 Could Double Your Money